Bioglan, CeNeS deal

CEN terminated a 2000 development and licensing deal with BGP to develop a sublingual opiate

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE